

June 6, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549

**Re: EyeGate Pharmaceuticals, Inc.
Registration Statement on Form S-1 (Registration No. 333-217418) -
Concurrence in Acceleration Request**

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC ("Wainwright"), as placement agent for the referenced offering, hereby concurs in the request by EyeGate Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 P.M. (Washington, D.C. time), or as soon as practicable thereafter, on June 8, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,

H.C. WAINWRIGHT & CO., LLC

By: /s/ Mark W. Viklund
Name: Mark W. Viklund
Title: Chief Executive Officer

430 Park Avenue | New York, New York 10022 | 212.356.0500
Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC
